Login / Signup

Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays.

April LiMichael SwansonNicole SullivanYing HomanDebbie NahasShreya MukhopadhyayHualin Helen LiYu CaoWeifeng XuHuaping TangKalpit A VoraZhifeng Chen
Published in: Bioanalysis (2023)
Background: MK-1654 is a fully human monoclonal antibody with YTE mutations currently in phase III clinical trials for prophylactic use in protecting infants from human respiratory syncytial virus infection. Materials & methods: We generated anti-idiotype (anti-ID) and anti-YTE antibodies against MK-1654 by panning with MorphoSys HuCal phage libraries, and used the antibodies in the development of MK-1654 pharmacokinetic (PK) and immune response (IR) assays. Results: Detection of MK-1654 in nonhuman primate and human nasal wash samples showed combined use of anti-ID and anti-YTE antibodies can deliver desired sensitivity and accuracy in PK studies. IR studies showed anti-ID can serve as suitable positive control in neutralizing antibody assays. Conclusion: Phage-derived anti-IDs and anti-YTEs are suitable for PK and IR assays.
Keyphrases
  • immune response
  • clinical trial
  • endothelial cells
  • high throughput
  • phase iii
  • open label
  • monoclonal antibody
  • dendritic cells
  • inflammatory response
  • respiratory syncytial virus
  • zika virus
  • dengue virus